Moderna shares rose 4.07% and 6.69% over the latest two U.S. trading sessions, a combined 11.04%, ahead of detailed data for its personalized mRNA cancer therapy, according to BlockBeats.
Phase 3 data schedule
Moderna and Merck are scheduled to present phase 3 INTerpath-001 results for intismeran autogene in high-risk melanoma at 22:30 Beijing time on Oct. 24, followed by an investor event at 01:00 on Oct. 25. The companies previously said the therapy with Keytruda met its recurrence-free-survival primary endpoint and a key distant-metastasis endpoint.
Reported market positioning
The report said Moderna closed at $242.08, with an intraday high of $243.98. TradingBeats monitoring identified a 10x isolated short of about 18,700 MRNA units worth roughly $4.518 million, entered near $237.04, with estimated liquidation at $248.37. Those position figures are third-party monitoring data and are not independently verified here.